



(11) **EP 3 131 927 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(51) Int Cl.:  
**C07K 16/28<sup>(2006.01)</sup> C07K 16/46<sup>(2006.01)</sup>**

(48) Corrigendum issued on:  
**23.12.2020 Bulletin 2020/52**

(86) International application number:  
**PCT/EP2015/057995**

(45) Date of publication and mention  
of the grant of the patent:  
**21.10.2020 Bulletin 2020/43**

(87) International publication number:  
**WO 2015/158671 (22.10.2015 Gazette 2015/42)**

(21) Application number: **15715285.1**

(22) Date of filing: **13.04.2015**

(54) **BCMA (CD269) SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR CANCER IMMUNOTHERAPY**

BCMA (CD269) -SPEZIFISCHE CHIMÄRE ANTIGENREZEPTOREN FÜR KREBSIMMUNTHERAPIE

RÉCÉPTEURS ANTIGÉNIQUES CHIMÉRIQUES SPÉCIFIQUES DE BCMA (CD269), UTILES DANS L'IMMUNOTHÉRAPIE DU CANCER

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB**  
**GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO**  
**PL PT RO RS SE SI SK SM TR**

(30) Priority: **14.04.2014 DK 201470212**

(43) Date of publication of application:  
**22.02.2017 Bulletin 2017/08**

(73) Proprietor: **Collectis**  
**75013 Paris (FR)**

(72) Inventor: **GALETTO, Roman**  
**F-75014 Paris (FR)**

(74) Representative: **Zacco Denmark A/S**  
**Arne Jacobsens Allé 15**  
**2300 Copenhagen S (DK)**

(56) References cited:  
**WO-A1-2012/079000 WO-A1-2013/072406**  
**WO-A1-2013/154760**

- **GARFALL ALFRED L ET AL: "Immunotherapy with chimeric antigen receptors for multiple myeloma.", DISCOVERY MEDICINE JAN 2014, vol. 17, no. 91, January 2014 (2014-01), pages 37-46, XP009181586, ISSN: 1944-7930**
- **CARPENTER R O ET AL: "B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 19, no. 8, 15 April 2013 (2013-04-15), pages 2048-2060, XP002727959, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-12-2422 [retrieved on 2013-01-23]**
- **FINNEY HELENE M ET AL: "Activation of resting human primary T cells with chimeric receptors: Costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCRzeta chain", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 172, no. 1, 1 January 2004 (2004-01-01), pages 104-113, XP002420497, ISSN: 0022-1767**

**EP 3 131 927 B8**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- JENSEN MICHAEL C ET AL: "Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells", IMMUNOLOGICAL REVIEWS, vol. 257, no. 1, Sp. Iss. SI, January 2014 (2014-01), pages 127-144, XP055156740,
- DAVID L PORTER ET AL: "Chimeric Antigen Receptor Therapy for B-cell Malignancies", JOURNAL OF CANCER, vol. 2042127, 1 January 2011 (2011-01-01), page 331, XP055118200, ISSN: 1837-9664, DOI: 10.7150/jca.2.331